Pegulicianine 39 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 39 mg

Reference Brands: Generic formulations marketed under different names

Category: Oncology Cancer Care

Pegulicianine is a Oncology Cancer Care product available as Injection in strengths 39 mg. It corresponds to the reference brand Generic formulations marketed under different names. Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Lorlatinib, marketed under the brand name Lorbrena in the USA, Canada, and Japan, and Lorviqua in the European Union, is an orally administered anti-cancer medication developed by Pfizer. It is used for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors are ALK-positive or ROS1-positive. Lorlatinib functions as an ATP-competitive inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), which are critical for cancer cell growth and survival. By selectively inhibiting these kinases, Lorlatinib disrupts ALK- and ROS1-mediated signaling pathways, suppressing tumor cell proliferation in ALK- and ROS1-overexpressing cancer cells.

A key feature of Lorlatinib is its ability to cross the blood-brain barrier, making it effective against central nervous system metastases often seen in ALK-positive NSCLC. Administered orally in tablet form, Lorlatinib offers a targeted therapy option for patients who have previously received other ALK-directed treatments. Its mechanism allows for precise inhibition of tumor growth while minimizing systemic exposure, making it a preferred therapy for advanced lung cancer with specific genetic mutations. Lorlatinib represents an important advancement in personalized oncology care, providing both efficacy and safety for patients with ALK- or ROS1-driven tumors.